Suchergebnisse - "Anjidani, Nassim"

PubPharm (35)

1

Comparative immunogenicity and safety of SpikoGen®, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults : An immuno-bridging clinical trial

enthalten in: International immunopharmacology | 2024

von Tabarsi, P. | Mamishi, S. | Anjidani, N. | +11

2

Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients with Multiple Sclerosis : A Phase IV, Post-marketing, Prospective, Multicenter Study

enthalten in: Archives of Iranian medicine | 2023

von Naser Moghadasi, A. | Ashtari, F. | Baghbanian, S. | +14

3

Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine : a phase 3 randomized placebo-controlled trial

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2023

von Tabarsi, P. | Anjidani, N. | Shahpari, R. | +9

4

Correction : Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

enthalten in: BMC cancer | 2022

von Allahyari, A. | Ehsanpour, A. | Najafi, B. | +30

ErratumFor: BMC Cancer. 2022 Sep 7;22(1):960. - PMID 36071409

5

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

enthalten in: BMC cancer | 2022

von Allahyari, A. | Ehsanpour, A. | Najafi, B. | +30

6

Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients : A Single-arm Clinical Trial

enthalten in: Clinical therapeutics | 2022

von Nafar, M. | Mostafaloo, N. | Firouzan, A. | +10

7

Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination : A randomized placebo-controlled trial

enthalten in: Immunology | 2022

von Tabarsi, P. | Anjidani, N. | Shahpari, R. | +5

8

Evaluating the safety and effectiveness of PegaGen® (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia : a post-marketing surveillance study

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2022

von Jenabian, A. | Ehsanpour, A. | Mortazavizadeh, S. | +7

9

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine : a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2022

von Tabarsi, P. | Anjidani, N. | Shahpari, R. | +9

10

Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients : a randomized, phase III, equivalency clinical trial

enthalten in: BMC cancer | 2022

von Allahyari, A. | Ehsanpour, A. | Najafi, B. | +30

ErratumIn: BMC Cancer. 2022 Dec 22;22(1):1348. - PMID 36550442